Anti-Human CD19 In Vivo Antibody - Low Endotoxin
- SKU:
- IVMB0328
- Product Type:
- In Vivo Monoclonal Antibody
- Clone:
- SJ25-C1
- Protein:
- CD19
- Isotype:
- IgG1 k
- Reactivity:
- Human
- Synonyms:
- CD19 Molecule
- Synonyms:
- Differentiation Antigen CD19
- Synonyms:
- B-Lymphocytes Surface Antigen B4
- Synonyms:
- T-cell Surface Antigen Leu-12
- Synonyms:
- CVID3
- Synonyms:
- B4
- Synonyms:
- B-lymphocyte Antigen CD19
- Research Area:
- Costimulatory Molecules
- Research Area:
- Immunology
- Endotoxin Level:
- Low Endotoxin
- Host Species:
- Mouse
- Applications:
- ELISA
- Applications:
- FC
- Applications:
- In Vivo
Description
Product Name: | Anti-Human CD19 In Vivo Antibody - Low Endotoxin |
Product Code: | IVMB0328 |
Size: | 1 mg, 5 mg, 25 mg, 50 mg, 100 mg |
Clone: | SJ25-C1 |
Protein: | CD19 |
Product Type: | Monoclonal Antibody |
Synonyms: | CD19 Molecule, Differentiation Antigen CD19, B-Lymphocytes Surface Antigen B4, T-cell Surface Antigen Leu-12, CVID3, B4, B-lymphocyte Antigen CD19 |
Isotype: | IgG1 k |
Reactivity: | Human |
Applications: | ELISA, FC, In Vivo |
Formulation: | This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
Purity: | ≥95% monomer by analytical SEC |
Product Preparation: | Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
Applications: | ELISA, FC, In Vivo |
Reactivity: | Human |
Host Species: | Mouse |
Specificity: | Clone SJ25-C1 recognizes an epitope on human CD19. |
Antigen Distribution: | CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. |
Immunogen: | NALM1 + NALM16 cells |
Concentration: | ≥ 2.0 mg/ml |
Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
Formulation: | This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
Purity: | ≥95% monomer by analytical SEC |
Preparation: | Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
Storage and Handling: | This antibody is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles. |